Diabetes can be managed and controlled with various injectable treatments available on the market: Insulin, GLP-1, and glucagon.

Diabetes is a severe and chronic disease that has been steadily increasing over the past few decades. Globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980; This reflects an increase in associated risk factors such as being overweight or obese. Recently, diabetes prevalence has risen faster in low- and middle-income countries than in higher-income countries*.

Treatments require high reliability in supply for high volumes, avoiding line stops, and reducing false rejects. Moreover, for containers like cartridges, integrating with drug delivery systems such as pen injectors, auto-injectors, and wearable is essential. For this reason, the container closure system/device compatibility must be thoroughly assessed to provide end-users and patients with reliable and effective administration means.

*Source: 2016 Global Report on Diabetes, World Health Organization